Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
A phase 2 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.
Overview
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) is a phase 2 interventional study registered as NCT02768363 by Candel Therapeutics, Inc., with 187 participants enrolled, started 2016-05 and due to reach its primary completion in 2024-11. Interventions recorded: aglatimagene besadenovec, placebo, valacyclovir. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Setting
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Phase
Phase 2
Sponsor
Candel Therapeutics, Inc.
Registry
Enrolled
187
Similar pages
not linked directly; found by shared links- TrialPhase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
- TrialA Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
- TrialAglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
- TrialCAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC